Lakefront Biotherapeutics NV (AMS:LKFT)
Netherlands · Delayed Price · Currency is EUR 25.06
-0.02 (-0.08%)
Last updated: Jun 16, 2026, 9:00 AM CET
AMS:LKFT Revenue
Lakefront Biotherapeutics NV had revenue of 7.56M EUR in the quarter ending March 31, 2026, a decrease of -90.73%. This brings the company's revenue in the last twelve months to 1.09B, up 234.71% year-over-year. In the year 2025, Lakefront Biotherapeutics NV had annual revenue of 1.17B with 268.41% growth.
Revenue (ttm)
1.09B
Revenue Growth
+234.71%
P/S Ratio
1.58
Revenue / Employee
1.48M
Employees
558
Market Cap
1.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | 849.32M | 268.41% |
| Dec 31, 2024 | 316.42M | 29.43M | 10.25% |
| Dec 31, 2023 | 287.00M | 9.62M | 3.47% |
| Dec 31, 2022 | 277.38M | -3.08M | -1.10% |
| Dec 31, 2021 | 280.46M | -249.81M | -47.11% |
| Dec 31, 2020 | 530.26M | -355.54M | -40.14% |
| Dec 31, 2019 | 885.80M | 578.13M | 187.91% |
| Dec 31, 2018 | 307.67M | 151.75M | 97.33% |
| Dec 31, 2017 | 155.92M | 4.31M | 2.84% |
| Dec 31, 2016 | 151.61M | 91.03M | 150.27% |
| Dec 31, 2015 | 60.58M | -29.44M | -32.70% |
| Dec 31, 2014 | 90.02M | -6.55M | -6.78% |
| Dec 31, 2013 | 96.57M | 4.35M | 4.71% |
| Dec 31, 2012 | 92.23M | -23.06M | -20.01% |
| Dec 31, 2011 | 115.29M | -21.27M | -15.57% |
| Dec 31, 2010 | 136.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Signify | 5.59B |
| Havas | 2.91B |
| Fugro | 1.85B |
| TKH Group | 1.76B |
| AMG Critical Materials | 1.53B |
| Basic-Fit | 1.42B |
| Corbion | 1.27B |
| Flow Traders | 820.82M |
Lakefront Biotherapeutics NV News
- 6 days ago - Lakefront Biotherapeutics announces EUR 50M share repurchase program - TheFly
- 7 days ago - Lakefront Biotherapeutics appoints Eric Hedrick chief medical officer - TheFly
- 5 weeks ago - Lakefront Biotherapeutics NV Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 - GlobeNewsWire
- 2 months ago - Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewsWire
- 2 months ago - Galapagos Announces Nomination of Gino Santini to its Board of Directors - GlobeNewsWire
- 2 months ago - Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings - GlobeNewsWire